PMID- 30197359 OWN - NLM STAT- MEDLINE DCOM- 20181030 LR - 20220321 IS - 1998-4138 (Electronic) IS - 1998-4138 (Linking) VI - 14 IP - 5 DP - 2018 Jul-Sep TI - Concurrent chemoradiotherapy with or without induction chemotherapy for the management of cervical lymph node metastasis from unknown primary tumor. PG - 1117-1120 LID - 10.4103/0973-1482.203594 [doi] AB - BACKGROUND: To determine the impact of concurrent chemoradiotherapy (CCRT) with or without induction chemotherapy over radiation alone for the treatment of patients of cervical lymph node metastasis from an unknown primary tumor. MATERIALS AND METHODS: A total of 96 patients with squamous cell histology of cervical lymph node metastases from unknown primary tumor were retrospectively reviewed. About 12 patients were treated with radiation alone (RT alone), 45 with CCRT, and 39 with induction chemotherapy followed by CCRT (ICCRT). RESULTS: Overall response rate (ORR) obtained with RT alone arm was 75%, whereas for CCRT, it was 86.7%. About 15.4% had a complete response (CR) after induction chemotherapy with 92.3% ORR after the completion of CCRT. At 2 years, the disease free survival (DFS) was 50% in RT alone, 73% with CCRT, and 62% with ICCRT, while the corresponding rates at 5 years were 50% for RT alone, 45% with CCRT, and 54% in ICCRT arm. CONCLUSION: Though we obtained a high ORR with concurrent or induction chemotherapy arm over RT alone, there is no clear advantage in the DFS. The nonrandomized nature of this trial and the potential for selection bias should definitely be taken into account while drawing comparisons from this trial. FAU - Khan, Mohsin AU - Khan M AD - Department of Radiotherapy, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, India. FAU - Siddiqui, Shahid A AU - Siddiqui SA AD - Department of Radiotherapy, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, India. LA - eng PT - Journal Article PL - India TA - J Cancer Res Ther JT - Journal of cancer research and therapeutics JID - 101249598 RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Adult MH - Aged MH - Chemoradiotherapy MH - Cisplatin/administration & dosage/adverse effects MH - Combined Modality Therapy MH - Disease-Free Survival MH - Female MH - Humans MH - Induction Chemotherapy MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Neoplasms, Unknown Primary/*drug therapy/pathology/*radiotherapy MH - Uterine Cervical Neoplasms/*drug therapy/pathology/*radiotherapy/secondary OTO - NOTNLM OT - Cervical lymph node metastases OT - chemo-radiation OT - induction chemotherapy OT - radiotherapy OT - unknown primary tumor COIS- There are no conflicts of interest EDAT- 2018/09/11 06:00 MHDA- 2018/10/31 06:00 CRDT- 2018/09/11 06:00 PHST- 2018/09/11 06:00 [entrez] PHST- 2018/09/11 06:00 [pubmed] PHST- 2018/10/31 06:00 [medline] AID - JCanResTher_2018_14_5_1117_203594 [pii] AID - 10.4103/0973-1482.203594 [doi] PST - ppublish SO - J Cancer Res Ther. 2018 Jul-Sep;14(5):1117-1120. doi: 10.4103/0973-1482.203594.